This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Making Medicines Work Better For You

OneFul is a pharmacy tech enterprise that has developed novel drug delivery products using patented automation and personalized medicine formulation software. In 2021, the company’s accredited pharma facility generated $5.8M in consolidated annual revenue, over $3M thru Q3 2022.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$81,410.97 Raised


Our innovative cardiovascular "polypill" combines 3-7 FDA-approved pharmaceuticals into a single capsule or gel packet tailored to your medical needs. In studies, our formulations have been shown to reduce the risk of heart attacks and strokes by 50% per year

Our robotic automation and online tools enable us to produce personalized treatments in partnership with telemedicine physicians at a price point as low as $1 per day, making personalized medications affordable and accessible to almost everyone.

Invest in OneFul to tap into the personalized medicine industry, which experts indicate that the industry will soon be a trillion-dollar sector. Unlike traditional “One-size-for-all” medicine, our precision technology combined with the latest pharmacogenomics science has the potential to transform healthcare by providing individualized therapies on a mass scale. Our team is equipped with patented robotics, multi-state accredited pharmacy licenses, and an entire operational pharmacy staff. The OneFul pipeline includes customized treatments for major chronic diseases such as diabetes, mental health, and Alzheimer's in the future. Don't miss out on the opportunity to revolutionize healthcare.

the pitch

OneFul Health's mission is to improve the quality of life for millions of patients, through personalized medicine produced with patented pharmacy technology. Our e-pharmacy platform combines precision medicine science and robotic automation to create multi-drug prescriptions as a capsule or easy-to-swallow gel packet. The company is currently focused on launching its personalized “polypill” product for cardiovascular patients and plans to scale to additional markets and health conditions, including mental health and diseases of aging,  in the next few years.

A Prescription for Efficient, Individualized Pharmaceutical Therapy

OneFul’s pharmaceutical technology platform is being designed to offer affordable and accessible prescription combination medications, customizable to a variety of health conditions and chronic diseases at the individual level.

*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.

Utilizing patented processes and innovative drug delivery technology, our digital platform is designed to consolidate many approved medications into a single capsule format, with a goal of improving patient adherence, and reducing any adverse effects from treatment. Our regulatory licenses allow us to go to market now without the uncertainty of government approvals using approved pharmaceuticals in high-purity forms. We work with partners who supply genomic analysis and digital health data, and algorithms to formulate each prescription to be the most effective combination of treatments possible for each person. 

The Problem & Our Solution

A Scalable Platform Built To Support Tens of Millions with Effective Chronic Disease Treatments 

For consumers managing chronic diseases and conditions, current drug therapies typically consist of multiple medications, requiring patients to take as many as 3-7 pills per day. According to recent data, 24% of adults in the U.S. take more than 3 pills per day and the rate of adherence to prescribed treatments is less than 50% (source, source), resulting in at least 100,000 preventable deaths, and $100B in preventable medical costs per year. (source)

In order to consolidate existing prescriptions as well as improve treatment outcomes, OneFul has developed the technology to combine multiple approved drugs and produce a single small capsule or flavored gel packets, containing high-purity doses of the same active drug ingredients. 

*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.

Our patented automation platform is capable of producing formulas on-demand, more accurately, and up to 100 times faster than traditional manual compounding, resulting in low-cost, highly-customized, multi-drug treatments. Many of our products cost as little as $1 per day and can be additionally personalized with microdosing to best suit the drug metabolism of each individual patient.

The Market & Our Traction

The Demand and Capacity to Change Personalized Medicine 

OneFul’s e-pharmacy has built a customer base of over loyal 3,500 patients, generating annual revenues of over $5M. 15-20% of existing customers surveyed indicate an interest in the cardiovascular polypill concept, translating to a potential waitlist of hundreds. We are in the process of negotiating contractual relationships with partners that include physician telemedicine networks, cardiology specialists, concierge clinics, and has had development contracts with major hospital systems. 

In order to meet growing demand, OneFul is building a direct-to-patient ecommerce platform, and, at present, the company has secured more than 13 patents for its robotic automation, personalized medicine process methods, and pharma-tech. Our strategic roadmap entails automation of 500 unique scripts per month by Q3 of 2023, and we believe we may incrementally increase monthly capacity to 5K by Q4 and 10K by mid-2024.

*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.

Why Invest

Help Simplify Medications and Grow a New Kind of Pharmaceutical Solution 

In OneFul’s opinion, we possess a unique opportunity built on an accredited established business combined with unmatched IP and innovation. We are on track to serve thousands of existing customers, and to reach millions of chronic disease sufferers, improving their health and daily quality of life. 

As of 2021, the company had successfully raised over $7M in funding which has been instrumental in developing our IP and building a commercial operation. 

Our future plans include market promotion, new partnerships, and scaling existing production operations to accommodate the growing demand for personalized therapies. Thank you for your investment in OneFul Health!

Click here to see if you qualify for our polypill!


6 Davis Drive
Durham, NC 27709

OneFul is a pharmacy tech enterprise that has developed novel drug delivery products using patented automation and personalized medicine formulation software. In 2021, the company’s accredited pharma facility generated $5.8M in consolidated annual revenue, over $3M thru Q3 2022.


Edison T Hudson
Edison T Hudson
CEO/CTO/Board Member/Founder

Edison is a serial entrepreneur with multiple exits and IPO experience. He is also recognized as a prolific inventor with over 30 patents, spending over 15 years in semiconductor automation in Silicon Valley and the EU. At iRobot Corporation, as Director of Research, he participated on the IPO team and led new business acquisitions and strategic technology roadmap analysis. His engineering and computer science expertise is combined with street-savvy business acumen, having concluded dozens of technology licenses and partnership agreements. He is a lifelong learner and researcher, a Morehead Scholar at the University of North Carolina, an MBA from Duke University, and studied machine learning and robotics at Oxford University U.K., where he spun out his first company. An excellent communicator, he was a speaker at the 2022 Precision Medicine World Conference in Silicon Valley. His passion and vision are that robotics and machine learning can democratize health using low-cost, safe, and more effective personalized treatments. He has assembled a team of experts and operational management that can leverage post-pandemic regulatory change. This team and his inventions are the foundation for a scalable digital health paradigm, economically delivering the benefits of personalized medicine to millions.

(Fulltime Employee)

Danny M Barnes
Danny M Barnes
Chief Pharmacy Officer, Board Member, President Triangle Compounding Pharmacy

Danny has spent the last 20 + years focused on serving patients and physicians with personalized sterile and non-sterile medications for complex needs. As president and operational executive of Triangle Compounding Pharmacy (TCP), the wholly owned compounding pharmacy operation of Oneful, he drove TCP to be the first compounding pharmacy in NC to meet national standards and be accredited by the Pharmacy Compounding Accreditation Board (PCAB). TCP was the first compounding pharmacy in NC to be registered as a Human Drug Outsourcing Facility (503B) to help physicians and hospitals meet critical patient needs by compounding crucial medications during drug shortages. Danny received his Pharm.D. from Campbell University and his Zoology degree at NC State University. As Chief Pharmacy Officer of Oneful Health, he is passionate about implementing cGMP quality robotic automation to modernize compounding pharmacy. His devotion to the highest quality products and services has generated a large, loyal community of patients and healthcare systems. He shares his regulatory and operational expertise through activities with state and national pharmacy organizations.

(Fulltime Employee)

Deon Joubert

Deon Joubert

Chairman of Board

Deon represents the Sanitarium Health & Wellbeing Group (AUS), a significant investor in Oneful Health Inc, where he has the role of Executive General Manager - Treasury & Advisory. Sanitarium is one of Australia/New Zealand's largest health food companies, which also operates major hospital facilities there. Deon has responsibility for a range of treasury and finance functions, banking, insurance, legal and M&A. Deon serves as director and/or secretary for most of the Sanitarium Health & Wellbeing Group entities and, as part of the Group’s executive, reports to the Chief Executive Officer. 

(Outside Board Member)

Worth Harris

Worth Harris

Board Member

Worth is a successful business executive, angel investor and board member for several startups. He contributes hands-on business management and growth advice. A significant long term investor in Oneful, he also invested in Panaceutics Nutrition Inc, the personalized nutrition spin out from Oneful. He has invested in a range of technology and business startups including ones in aseptic food processing, next generation water filtration systems, alternative transportation and real estate. University of North Carolina, Business degree.

(Outside Board Member)

Eva Doss

Eva Doss

Board Member

Eva is President and CEO of The Launch Place, a venture fund, a long-term investor in Oneful and a board member. She brings twenty-five years of experience in business consulting, strategic planning, business development and equity investment fund establishment and management in the United States and Europe. Having secured over $50 million in private and public investments for new business ventures, she worked with Booz Allen, Research Triangle Institute, USAID, and regional development groups in Virginia. Executive Certificate in Management and Leadership, MIT Sloan School.

(Outside Board Member)

Angela Keck

Angela Keck

Secretary/Treasurer, Chief Accountant and Human Resources Administrator

Angela is a CPA, MBA who has served Triangle Compounding Pharmacy (TCP) for 16 years, and led the outside financial review of Oneful and TCP. She was recently appointed to serve as Secretary/Treasure for Oneful Health Inc. She has extensive experience with financial statement preparation, forecasting, payroll, human resource management, benefit planning and implementation, complex problem solving and pharmacy policy development. Certified Public Accountant with 20 years’ experience, MBA, experience with resolving tax issues, audits, business mergers and acquisitions with the related due diligence. BA and MBA from Meredith College.

(Fulltime Employee)

Mark Friedman

Mark Friedman

Lead Financial Consultant

Mark is an experienced business executive and angel investor. As a fractional financial advisor through Lakeview Business Advisory and Management, he was a key architect of Oneful’s financial restructuring after the spin-out of the Panaceutics Nutrition entity. With expertise in various industries and company sizes, including management in a private equity-owned Dental Support Organization, his experience ranges from startup to mid-sized companies. Through RTP Capital, an angel investor he co-founded and is President, he and others were early investors in Oneful Health and has invested in numerous other early-stage companies. He has been involved in various non-profit organizations as a board member, has his BA from the University of Rochester and MBA from the Fuqua School of Business, Duke University.

(Fractional Contractor )

Walter Daniels

Walter Daniels

Lead Legal Counsel

Walter has been the Company's lead outside legal advisor, helping to organize and structure Oneful since its inception in 2013. He is founder of Daniels & Daniels, P.A., a law firm that has helped thousands of Research Triangle startups and public companies become organized and compliant growth companies. His practice covers corporate organization, fiduciary guidance, SEC regulatory compliance, employment law, intellectual property, and the transactional needs of technology-based emerging growth companies. For the past decade, he has served as Chairman of the NC Small Business Technology Development Center and on numerous company boards and commissions, including the Council for Entrepreneurial Development. He has received a 10 rating by Martindale Hubbell AVVO®, and was selected as among Best Lawyers® in America. University of North Carolina-Chapel Hill, BA, JD, Duke University, MA.

(Outside Counsel)

Staton Noel

Staton Noel

Board of Advisors - Chief Science Advisor

Staton has 25 years’ of experience in biotechnology and pharmaceutical research to help create products for individual health and wellness needs. He co-founded and is CEO of Panaceutics Nutrition Inc, a technology leader in personalized and clinical nutrition. As a molecular pharmacologist at Glaxo-Smith Kline, he lead multiple drug discovery projects. He spent five years as Director of the Office of Innovation Commercialization at UNC-Greensboro, managing and licensing intellectual property and negotiating complex interinstitutional agreements. Staton holds a BS in Biochemistry, MS in Gerontology, an MBA, and has authored multiple peered reviewed research articles.

(Investor, Outside Advisor)

Andrew Gunn, III

Andrew Gunn, III

Lead Regulatory and Quality Consultant

Andy is Oneful’s senior regulatory and quality consultant, having worked full-time as Vice President of Quality and Regulatory Affairs for the company for 3 years. Formerly on FDA staff with extensive regulatory science expertise and clinical research management experience. Over thirty years as a regulatory consultant for biotech, pharmaceutical, and medical devices. Broad range of regulatory roles at FDA, Abbott, Becton Dickinson, Boston Scientific, Novartis, and Intermountain Healthcare. At St. Jude Children’s Research Hospital, he was the Global Head of Clinical Research and Regulatory Affairs. North Carolina State University, BS Cell Biology. Drexel University College of Medicine, graduate work in Molecular Medicine.

(Fractional Contractor)

Thomas Roberg

Thomas Roberg

Board of Advisors - Investor Advisor - Former Board Chairman

Tom is an early investor in Oneful and served on the Board for six years, two years as Chairman. Active in several startups as investor, consultant, and board member. Founding investor of BioMarck Pharmaceuticals and a key investor in Advanced Liquid Logic, a company acquired by Illumina for over $100 million. His industry and government connections have been very helpful to the Company and he continues to provide business insights as a board observer. 

(Investor - Board Observer)

Gary Epler, M.D.

Gary Epler, M.D.

Board of Advisors - Lead Medical Advisor

Gary is a former Harvard Medical School professor, and an internationally known physician and thought leader on medicine, nutrition, peak performance, and executive health. An advisor to Brigham and Women's Hospital for over twenty years, he has impacted people's lives worldwide with innovations in medicine, notably for the treatments he developed for a rare lung disease that he discovered. He serves startups and private equity-backed companies in roles as medical/surgical clinical consultant and fractional Chief Medical Officer, helping with product development, capital raise, and closing sales. Medical Degrees from Tulane Medical School and in epidemiology at Harvard Channing School of Public Health.

(Fractional Consultant)

Garrett Ruhland

Garrett Ruhland

Board of Advisors - Digital Health Science, Web Marketing Advisor

Garrett is founder of two San Francisco based web platform companies focused on digital health, personalized wellness, and web based healthcare. As Founder-CEO of BioMarker Labs,, he created a flexible platform to address the emerging digital health demands. He has demonstrated innovations in software and algorithm development applied to biotechnology, personalized nutrition and telemedicine practices, with current developments demonstrating the use of blockchain to democratize healthcare. Skilled in online enterprise sales, clincal research services, with a science background in molecular & cellular biology. His strong business strategy and digital health expertise makes him an ideal partner for Oneful. Bachelor of Science (BS) focused in Molecular Biology from Duke University. 

(Fractional Consultant)

Bhaskar Venepali, PhD

Bhaskar Venepali, PhD

Board of Advisors - Pharmaceutical Chemist, Industry Expert

Bhaskar is President / CEO / Founder of CVenti Chem, a specialized contract drug manufacturer, he is a proven leader with excellent industry knowledge and contacts. As an experienced executive, he also is a scientist with technical knowledge in the custom synthesis of active pharmaceutical ingredients and complex contract pharmaceutical manufacturing processes. His established relationships with key global pharmaceutical supply chains will be a major aid to Oneful. He is a long-time investor in Oneful Health and has invested in many startups. He currently serves on Board of Directors at North Carolina Biotechnology Center and as a Trustee at North Carolina A&T University. PhD in Organic Chemistry, Osmania University, MBA from University of Rochester Simon School.

(Investor, Outside Advisor)


OneFul Health, Inc.
Jun 2, 2023
$15k - $1.24M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Subscriber shall appoint the Board of Directors of the Company (acting as a majority) (the “Board”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the Board determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the Board for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

By subscribing to the Offering, each Stockholder agrees that inherent in the proxy rights granted to the Board of Directors are the rights to give and receive notices and communications, execute any instrument or document that the Board determines is necessary or appropriate in the exercise of its authority under this instrument, and to take all actions necessary or appropriate in the judgment of the Board for the accomplishment of the foregoing, and further, that these rights shall survive death of an individual shareholder.

Investment Incentives & Bonuses*


• First Birds Bonus: Invest within the first two weeks and receive 25% bonus shares.

• Early Birds Bonus: Invest in weeks three & four and receive 15% bonus shares.

• Early Bonus: Invest in weeks five & six and receive 10% bonus shares. 


• Company Bonus: Invest $1000+ and receive 5% bonus shares. 

• Silver Bonus: Invest $5,000+ and receive 15% bonus shares.

• Gold Bonus: Invest $10,000+ and receive 20% bonus shares.

• Platinum Bonus: Invest $25,000+ and receive 25% bonus shares

The 10% OneFul Health Inc’s existing shareholders:

• OneFul Health Inc’s existing shareholders, customers, and partners including prescribing physicians/nurses, and contractors receive a bonus of 10% in addition to any of the above bonuses.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

OneFul Health, Inc will also offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 /share, you will receive 10 additional shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Bonus Stacking: Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and 10% OneFul Health existing shareholder bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Any expense labeled “Travel and Entertainment”. Vendor payments.


Article Image
The Polypill at 20 — What Have We Learned?

These studies show similar or even improved risk-factor control in patients treated with a polypill as compared with usual care. There is also robust evidence that the combination pills have an acceptable side-effect profile.

Article Image
This Daily Pill Cut Heart Attacks by Half. Why Isn’t Everyone Getting It?

Giving people an inexpensive pill containing generic drugs that prevent heart attacks — an idea first proposed 20 years ago but rarely tested — worked quite well in a new study, slashing the rate of heart attacks by more than half among those who regularly took the polypills.

Article Image

Personalized medicine is an emerging practice of medicine that uses an individual's genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease.



1,250. What's 1,250? 1,250 could equal $1M

1,250 polypill patients/ month could potentially grow revenues to $1M a year according to our sales model.  We project to retain a high % of customers each month since we are one of the only low-price sources for CVD polypills in the USA.

~60 million people. 24% of adults in the U.S. take more than 3 pills per day. There are 250m+ adults in the US. Yes, that's a big number who OneFul Health's personalized polypill could hopefully serve.

In the short time since we launched the raise, we announced 2 major partnerships which have the potential to put us in front of thousands of additional providers and patients who can take a < 5 min survey to see if they qualify for the personalized polypill. That's on top of our existing customer base and health provider network. We already have a list of other potential partners who reached out to us because they saw our raise. 

Thank you to everyone who has invested so far. 

To grow OneFul Health together, here's all we ask you to do. 

Share our simple survey to see who in your network may qualify for the personalized polypill.

We already have applications coming in.

Wishing you wealth and health.


Why Dr. Schwab Invested in OneFul

Dr. Andrew Schwab - VC and Cardiovascular Patient Explains Why He Invested

Dr. Andrew Schwab is an investor in OneFul Health Inc based on his deep understanding of the healthcare industry and his background in technology startups.   He also suffered a cardiovascular event in the past two years, and explains why OneFul's personalized polypill is so important to him personally, and why he believes it solves big problems for chronic disease patients like him.

Why he invests in OneFul Health - 3 minutes -  Youtube - Why Dr. Schwab Invested in OneFul; 

To view the full 20-minute interview describing his journey from an investor to being a cardiovascular patient who understands first-hand the benefits of OneFul's personalized polypill, visit OneFul's website at .

This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.


Why Dr. Schwab Invested in OneFul

Dr. Andrew Schwab is an investor in OneFul Health Inc based on his deep understanding of the healthcare industry and his background in technology startups.   He also suffered a cardiovascular event in the past two years, and explains why OneFul's personalized polypill is so important to him personally, and why he believes it solves big problems for chronic disease patients like him.

Why he invests in OneFul Health - 3 minutes -  Youtube - 

To view the full 20 minute interview describing his journey from investor to being a cardiovascular patient who understands first  hand the benefits of OneFul's personalized polypill, visit OneFul's website at  


Preventable Cardiovascular

Every 34 seconds in the United States, an adult dies from preventable cardiovascular disease (CVD).1 These are mothers, fathers, sisters, brothers, and friends—all gone because of a disease that is largely preventable.

  • 4.1 Million not taking aspirin or blood thinners as recommended
  • 67.8 Million with uncontrolled BP (≥ 130/80 mm Hg)
  • 37.5 Million not taking statins as recommended

The need is great, and the market size is enormous. The North America cardiovascular drug market size is around US $ 31.85 Bn in 2022 and is projected to reach US $ 43.40 Bn in 20302.

Twenty years ago next month, a paper entitled “PolyPill - “A strategy to reduce cardiovascular disease by more than 80%” Wald, Law ( Since then over 30,000 patients in other countries have used a version of the polypill, which has shown to reduce the risk of major cardiac events by 50% on average. So this is a way to help control this terrible disease – the polypill.

Until now, no polypill product or service exists in the USA, and no personalized, patient-specific product has been offered anywhere in the world. 

Oneful is the First Pharmacy Online Platform to enable low-cost, personalized and precision cardiovascular prevention using its robotic “Single-pill combination” technology.    Without this technology, accredited pharmacy infrastructure, and physician partnerships, no other company can provide such a product at an affordable price, as low as $1.00 a day. Based on our extensive industry technical knowledge and research and 20 years of operating experience in the compounding pharmacy industry, our management team believes that our patented technology and regulatory plan give us substantial competitive advantages to manufacture precision treatments that reduce cardiac events profitably at affordable costs to consumers.

Invest now, as this is going to happen. Will OneFul own the whole personalized polypill market forever? Unlikely once Big Pharma and Insurance start to see the savings of lives and budgets due to the reduction in this costly disease. Get onboard before the big guys get out their checkbooks!


2 US Cardiovascular Drugs Market Analysis Report [2022-30] I Insights10 (,a%20CAGR%20of%205.4%25%20during%20the%20forecast%20period.)


OneFul and Geneticure Solution to High Blood Pressure

Making Heart Medicines Work Better with Genomics-  Geneticure and OneFul Health Partner for Precision Polypills 

Geneticure Inc ( and OneFul Health Inc ( are teaming up to combine genomic-based formulation and personalized medicine to create precision treatments that work better for cardiovascular patients. Their joint mission is to help prevent heart attacks and strokes, focusing on better high-blood pressure treatments. 

Hypertension or high blood pressure is a significant risk for several medical conditions, including coronary artery disease, stroke, heart failure, atrial fibrillation, vision loss, chronic kidney disease, and dementia. According to the CDC 2020 data, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.

Geneticure is a team of hypertension expert scientists and doctors based in Rochester, Minnesota, home of the Mayo Clinic —also an investor in Geneticure. For ten years, Geneticure's scientists have put science and innovation to work, taking personalized medicine to the next level, unmatched in the world of pharmacogenomics. With their home-collected test using the DNA on a cheek swab, Geneticure recommends which hypertension medication(s) may give the biggest drop in blood pressure. This information, supplied to specialist cardiologists, will aid OneFul Health in formulating the most effective precision polypill for each individual. 

OneFul is leading the way with the first-ever precision cardiovascular polypill combining three to seven FDA-approved cardiovascular pharmaceuticals into one small capsule or gel packet. Hypertension often can only be controlled by using multiple medication classes at dosages that vary significantly among individuals. OneFul will send HIPAA-secured data generated by Geneticure to partner cardiologists or the person's doctor. Geneticure's custom report enables OneFul and its physician partners to formulate a precision polypill for hypertension optimized to each person's genetics. The optimized multi-drug prescription to control hypertension and other heart risks is transmitted to OneFul's accredited pharmaceutical facility where it is made on demand using it's patented robotic process to ensure quality. This personalized polypill is then made on demand using only certified lab-tested purity and cardiovascular drugs proven safe in trials of over 30,000 patients.

Both companies are committed to quality care and direct-to-patient services to create custom treatments that improve the quality of life and ease patient adherence. Geneticure agrees to work with OneFul Health to develop medical protocols for precision polypills and to study the benefits to patients of their joint development. The Geneticure and the OneFul Health teams are excited by the potential to improve cardiovascular treatment, bringing precision cardiology to market.  


Will a Personalized PolyPill Reduce Your Heart Risk?

Based on our online polypill qualification survey, OneFul Health is adding 10 new candidates daily to its waiting list by for a personalized cardiovascular polypill combining 3 to 7 pills into one convenient, made-to-order capsule.

Our five-minute online HIPAA secure survey gathers the information that allows us to screen the best candidates for this personalized combination treatment. Working with HeartBeat Health's cardiologist or doctor, we can make the optimal formulation to reduce cardiovascular risks.  Our combination of approved medications has been shown in clinical trials to reduce the annual risk of heart attack and stroke by up to 50%.  

Will this innovation help you or your loved ones have a better chance at a healthy longer life?

Take the survey here and let’s see how we can help. 


Better Than AI? Closed Loop Wearable Enabled Robotic Treatments

Cardiovascular health is a medical domain where AI may be a fantastic tool for new drug and treatment discovery, but it may not be a panacea. Dr. Eric Topol reported on a continuous blood pressure monitoring bracelet about advances in non-compression-based wearable tech ( A new study ( reported about substantial variation in the blood pressure response to various antihypertensive medications between individuals, raising the possibility of need for personalized therapy. At OneFul Health, we are working with teams that will make AI will be a fantastic tool to predict the starting formulation for a precision polypill at the individual level. AIs will best integrate an individual's digital health profile, including pharmacogenomics, metabolic factors, and epigenetics. So, AIs will likely soon provide the most competent predictive personalized treatment recommendations. However, even such data-intensive AI-based treatment prescriptions cannot readily include the complete real-world individual picture, distorted by the hyper-complexity of current drug interactions, their microbiome health, diet and exercise. That is where closed-loop continuous monitoring and communication from daily wearables like an Apple Watch or Fitbit come into play. Such devices linked to AI, may bring about a whole new model for several aspects of cardiovascular preventative care. Using tech tools like Zio (, as an in-home continuous monitor for electrophysiological factors by HeartBeat Health, (,  and other cardiologists is already accepted. Dynamic control in all complex systems has historically been optimized only by using near real-time feedback, as taught by famed MIT mathematician Norbert Wiener ( With broadband infrastructure and the pervasive adoption of personal wearables, the time is here to embrace the use of closed-loop continuous monitoring and communication from daily wearables, as it has the potential to revolutionize several aspects of cardiovascular preventative care. At OneFul Health, we believe that predictive AI will unlikely be successful at preventing cardiovascular events without closing the loop at the individual level. A modernized protocol that augments AI recommendations with closed-loop continuous monitoring and communication from daily wearables to optimize precision polypills for personalized treatments can be a cardiovascular care game-changer. We believe this closed-loop approach will be better than any AI, for complex diseases such as mental health, where wearable devices or simple smartphone feedback can help formulate optimal therapies for individuals.


Personalized Polypill for Underserved

An important article in USA Today is "Why are so many Black patients dying from heart failure?" .Black patients are more likely to die of heart failure. Why? ( ).  Dr. Munoz et al at Vanderbilt University Medical Center researched an approach to a partial solution and was published in the New England Journal of Medicine in 2019. ( |. Until recently, the polypill concept rarely included all the right drugs or therapeutic doses to treat heart failure. Our work at removes that limitation allowing individualized physician-prescribed combinations in a single personalized polypill that can include heart-failure medications while keeping out-of-pocket costs typically to $1/day. Remote access issues are addressed by cooperating with leading telemedicine specialist cardiologist networks, like partners at HeartBeat Health. This new approach to personalized cardiovascular polypills prescribed online and accurately made with robotic on-demand manufacturing can potentially reduce cardiovascular risks in populations not adequately covered by insurance in remote, underserved locations. Personalized polypills reduce most common cardiovascular risks and can be prescribed and delivered directly to at-risk individuals. The post-COVID era will show how such technologies as OneFul.Health has developed can be employed to address health equity. 


HeartBeat Health and Oneful Health For Personalized Cardiology

Personalized Medicine Meets Virtual Care Cardiology:

Heartbeat Health and OneFul Health Partner to Prevent Heart Attacks and Strokes

March 28, 2023,  New York, NY and Research Triangle Park, NC 

Heartbeat Health and OneFul Health have teamed up to bring telemedicine and personalized medicine together, providing individuals with unique treatments to help prevent heart attacks and strokes, delivered right to their homes.

Heartbeat Health is founded by Dr. Jeffrey Wessler, a cardiologist-entrepreneur who leveraged his academic expertise to create a new standard for Virtual-First Cardiology care. Heartbeat is revolutionizing cardiovascular care, one virtual intervention at a time, and is the perfect partner for OneFul. This combination of innovative healthcare technology companies will deliver direct-to-patient personalized cardiovascular disease prevention and management services.

OneFul is leading the way with the first-ever precision cardiovascular polypill combining three to seven FDA-approved cardiovascular pharmaceuticals into one small capsule.  Using only certified lab-tested purity and proven safe cardiovascular drugs trialed in over 30,000 patients, OneFul formulates personalized pharmaceutical treatments with its patented pharm tech automation platform, invented by founder and robotics expert Edison Hudson.

OneFul will send HIPAA-controlled data about pre-qualified polypill patients to Heartbeat, whose cardiologists will qualify patients for personalized polypill treatments, creating custom prescriptions that match each patient's medical needs. Their multi-drug prescription is then transmitted to OneFul's accredited pharmaceutical facility, managed by 20+ year veteran Pharmacist Danny Barnes. His PharmD team reviews and accurately fills each script using high-accuracy technology.

Both companies are committed to quality care and direct-to-patient services, making specialized cardiology consultations accessible and fast to schedule, along with custom treatments that make life and medication adherence easier for patients. Plans include integrating pharmacogenomics and in-home biomarker testing to improve treatment effectiveness further and reduce adverse effects. HeartBeat agrees to work with OneFul Health to create medical protocols for precision polypills that can be applied to any patient by their national network of cardiologists.

Heartbeat Health and OneFul Health teams are excited by the potential to improve cardiovascular treatment, providing the best in telemedicine and personalized medicine to prevent heart attacks and strokes and ushering in a new era of personalized cardiovascular care. 


What is the Market for Personalized Polypill

Watch Edison Hudson, CEO/Founder speak about Oneful Personalized, Precision, Preventative Polypill - 

Imagine having the power to change lives and prevent heart disease in millions of Americans. With our Cardiovascular Precision Preventative Polypill, or CVD-P3, we have the opportunity to make a significant impact in the world of medicine. Some of you may have had questions about our product and its potential impact. Rest assured, the market for our product is enormous. Over 14 million Americans have diagnosed coronary artery disease, and a large portion of these individuals could benefit from using CVD-P3.

Our product is specially designed for patients who take multiple post-operation drugs to reduce risk. This includes patients who have received stents and coronary artery bypass graft surgery, which amounts to 2 million and 340,000 people per year, respectively. And it doesn't stop there. CVD-P3 can also be formulated to address specific genomic risk factors, common in some families - 27.8 million people over 20 years of age.

With the impact of COVID-19, the risks for heart disease have only increased. Dr. Eric Topol, in his recent article on Substack, mentions the 1.7-fold risk of heart attack and 1.6-fold increased risk of stroke. This means that there is an even greater need for preventative measures like CVD-P3.

But let's talk about the numbers. Our model predicts that we can achieve revenue of $100M by serving just 1.5 million customers per year - a feasible number with 25 of our robotic compounders. And that's just the beginning. Imagine the potential impact of our future pipeline, which includes addressing diabetes, metabolic diseases, and mental health.

So, let's take control of the future of medicine and make a real difference in the lives of millions. Join us in our mission to prevent heart disease and pave the way for a healthier world. Listen to Edison Hudson, our CEO explain more about our revolutionary CVD-P3 personalized product. 

Data Sources: ;,stents%20implanted%20per%20year%20in%20the%20United%20States. ;,grafted%20onto%20the%20heart%20to%20bypass%20blocked%20arteries. ;,cardiovascular%20disease%20can%20be%20identified%20using%20family%20history. ; 

StartEngine Forward Looking Statements:

The statements in the article are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this update are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into OneFul Health, Inc..



Adam Sampson


3 months ago

Being in healthcare, I do like the general concept. People take on average more than 10 pills a day, and it can be quite difficult to keep up with them. Although most patients stay on their current medications for a long period of time, what happens when a medication is changed? If a patient is ill, or a change in their health/medications and the provider wants to change a dose or get rid of a medication, how does the patient get replacement? If their provider wants them to stop of the meds in the mix today, what does the patient do? Is 5 million your revenue from 2022?




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.